FDA
-
-
-
-
-
-
-
Mineralys presents lorundrostat data for hypertension patients with kidney disease
-
-
-
-
-
-
-
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
-
-
-
-
-
-
-
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
-
-
-
-
-
-
-
Mineralys completes enrollment in sleep apnea drug trial
-
-
-
-
-
-
-
Mineralys Therapeutics (MLYS) announces positive results from Phase 3 Launch-HTN trial
-
-
-
-
-
-
-
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
-
-
-
-
-
-
-
Mineralys Therapeutics (MLYS) Announces Positive Topline Results from Launch-HTN and Advance-HTN Trials of Lorundrostat
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

